<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Guanylate cyclase stimulators for pulmonary hypertension - Wardle, AJ - 2016 | Cochrane Library</title> <meta content="Guanylate cyclase stimulators for pulmonary hypertension - Wardle, AJ - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011205.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Guanylate cyclase stimulators for pulmonary hypertension - Wardle, AJ - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011205.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011205.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Guanylate cyclase stimulators for pulmonary hypertension" name="citation_title"/> <meta content="Andrew J Wardle" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="aw7084@my.bristol.ac.uk" name="citation_author_email"/> <meta content="Matthew J Seager" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Richard Wardle" name="citation_author"/> <meta content="Queens Medical Centre" name="citation_author_institution"/> <meta content="Robert MR Tulloh" name="citation_author"/> <meta content="Bristol Royal Hospital for Children and Bristol Heart Institute" name="citation_author_institution"/> <meta content="J Simon R Gibbs" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD011205.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/08/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011205.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011205.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011205.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Guanylate Cyclase; Hypertension, Pulmonary [*drug therapy]; Pyrazoles [*therapeutic use]; Pyrimidines [*therapeutic use]; Randomized Controlled Trials as Topic; Time Factors; Walking" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011205.pub2&amp;doi=10.1002/14651858.CD011205.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011205\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011205\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011205.pub2",title:"Guanylate cyclase stimulators for pulmonary hypertension",firstPublishedDate:"Aug 2, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011205.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011205.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011205.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011205.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011205.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011205.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011205.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011205.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011205.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011205.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1950 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011205.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-sec-0078"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-sec-0068"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/appendices#CD011205-sec-0083"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/table_n/CD011205StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/table_n/CD011205StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Guanylate cyclase stimulators for pulmonary hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#CD011205-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Andrew J Wardle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#CD011205-cr-0003">Matthew J Seager</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#CD011205-cr-0004">Richard Wardle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#CD011205-cr-0005">Robert MR Tulloh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information#CD011205-cr-0006">J Simon R Gibbs</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information/en#CD011205-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 August 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011205.pub2">https://doi.org/10.1002/14651858.CD011205.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011205-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011205-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011205-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011205-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011205-abs-0001" lang="en"> <section id="CD011205-sec-0001"> <h3 class="title" id="CD011205-sec-0001">Background</h3> <p>Pulmonary hypertension is a condition of complex aetiology that culminates in right heart failure and early death. Soluble guanylate cyclase (sGC) stimulators are a promising class of agents that have recently gained approval for use. </p> </section> <section id="CD011205-sec-0002"> <h3 class="title" id="CD011205-sec-0002">Objectives</h3> <p>To evaluate the efficacy of sGC stimulators in pulmonary hypertension.</p> </section> <section id="CD011205-sec-0003"> <h3 class="title" id="CD011205-sec-0003">Search methods</h3> <p>We searched CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE, EMBASE and the reference lists of articles. Searches are current as of 12 February 2016. </p> </section> <section id="CD011205-sec-0004"> <h3 class="title" id="CD011205-sec-0004">Selection criteria</h3> <p>We selected randomised controlled trials (RCTs) involving participants with pulmonary hypertension of all ages, severities and durations of treatment. </p> </section> <section id="CD011205-sec-0005"> <h3 class="title" id="CD011205-sec-0005">Data collection and analysis</h3> <p>AW, MS and RW independently selected studies, assessed evidence quality and extracted data. This process was overseen by RT and SG. All included studies were sponsored by the drug manufacturer. </p> </section> <section id="CD011205-sec-0006"> <h3 class="title" id="CD011205-sec-0006">Main results</h3> <p>Five trials involving 962 participants are included in this review. All trials were of relatively short duration (&lt; 16 weeks). Due to the heterogenous aetiology of pulmonary hypertension in participants, results are best considered according to each pulmonary hypertension subtype. </p> <p>Pooled analysis shows a mean difference (MD) increase in six‐minute walking distance (6MWD) of 30.13 metres (95% CI 5.29 to 54.96; participants = 659; studies = 3). On subgroup analysis, for pulmonary arterial hypertension (PAH) there was no effect noted (6MWD; MD 11.91 metres, 95% CI −44.92 to 68.75; participants = 398; studies = 2), and in chronic thromboembolic pulmonary hypertension (CTEPH) sGC stimulators improved 6MWD by an MD of 45 metres (95% CI 23.87 to 66.13; participants = 261; studies = 1). Data for left heart disease‐associated PH was not available for pooling. Importantly, when participants receiving phosphodiesterase inhibitors were excluded, sGC stimulators increased 6MWD by a MD of 36 metres in PAH. The second primary outcome, mortality, showed no change on pooled analysis against placebo (Peto odds ratio (OR) 0.57, 95% CI 0.18 to 1.80). </p> <p>Pooled secondary outcomes include an increase in World Health Organization (WHO) functional class (OR 1.53, 95% CI 0.87 to 2.72; participants = 858; studies = 4), no effect on clinical worsening (OR 0.45, 95% CI 0.17 to 1.14; participants = 842; studies = 3), and a reduction in mean pulmonary artery pressure (MD −2.77 mmHg, 95% CI −4.96 to −0.58; participants = 744; studies = 5). There was no significant difference in serious adverse events on pooled analysis (OR 1.12, 95% CI 0.66 to 1.90; participants = 818; studies = 5) or when analysed at PAH (MD −3.50, 95% CI −5.54 to −1.46; participants = 344; studies = 1), left heart disease associated subgroups (OR 1.56, 95% CI 0.78 to 3.13; participants = 159; studies = 2) or CTEPH subgroups (OR 1.29, 95% CI 0.65 to 2.56; participants = 261; studies = 1). </p> <p>It is important to consider the results for PAH in the context of a person who is not also receiving a phosphodiesterase‐V inhibitor, a contra‐indication to sGC stimulator use. It should also be noted that CTEPH results are applicable to inoperable or recurrent CTEPH only. </p> <p>Evidence was rated according to the GRADE scoring system. One outcome was considered high quality, two were moderate, and eight were of low or very low quality, meaning that for many of the outcomes the true effect could differ substantially from our estimate. There were only minor concerns regarding the risk of bias in these trials, all being RCTs largely following the original protocol. Most trials employed an intention‐to‐treat analysis. </p> </section> <section id="CD011205-sec-0007"> <h3 class="title" id="CD011205-sec-0007">Authors' conclusions</h3> <p>sGC stimulators improve pulmonary artery pressures in people with PAH (who are treatment naive or receiving a prostanoid or endothelin antagonist) or those with recurrent or inoperable CTEPH. In these settings this can be achieved without notable complication. However, sGC stimulators should not be taken by people also receiving phosphodiestase‐V inhibitors or nitrates due to the risks of hypotension, and there is currently no evidence supporting their use in pulmonary hypertension associated with left heart disease. There is no evidence supporting their use in children. These conclusions are based on data with limitations, including unavailable data from two of the trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011205-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011205-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011205-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011205-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011205-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011205-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011205-abs-0003" lang="en"> <h3>Soluble guanylate cyclase stimulators for raised blood pressure within the lungs</h3> <p><b>Review question</b> </p> <p>We reviewed the use of a set of drugs, soluble guanylate cyclase stimulators, for the improvement of symptoms in participants with pulmonary hypertension (PH). This was in comparison to current treatment or no treatment. </p> <p><b>Background</b> </p> <p>PH involves high blood pressure in the blood vessels of the lungs. This causes shortness of breath and reduces the ability to exercise, leading to faints and dizziness. PH can cause the heart to fail, leading to a shortened life. PH is not a single disease, but includes a group of diseases. Key PH types for this review include pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and PH due to left heart disease. </p> <p><b>Study characteristics</b> </p> <p>This evidence is current to February 2016. Males and females of all ages diagnosed with PH were included in this review. We selected only randomised clinical trials. All trials used a comparison to no treatment. Trial durations ranged from 12 to 16 weeks. This review involves five trials on 962 participants. All included studies were sponsored by the maker of the drug. </p> <p><b>Key results</b> </p> <p>Soluble guanylate cyclase stimulators appear to reduce lung pressures and improve exercise capacity in PAH and recurrent or inoperable CTEPH, but not in PH due to left heart disease. It is uncertain if these drugs have an effect on death rates and general health decline, or if they may be associated with serious side effects. There is evidence that suggests these drugs should not be taken at the same time as phosphodiesterase‐V inhibitors. </p> <p><b>Quality of the evidence</b> </p> <p>One outcome was considered to be high quality according to the GRADE scoring system. Two were considered moderate strength and eight outcomes were considered low or very low strength. This means the results reported may not represent the true effect. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011205-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011205-sec-0078">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011205-sec-0122">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011205-sec-0078"></div> <h3 class="title" id="CD011205-sec-0079">Implications for practice</h3> <section id="CD011205-sec-0079"> <p>In PAH, sGC stimulators reduce mean pulmonary artery pressures and, in the absence of concomitant phosphodiesterase‐V inhibitors, improve exercise capacity. Based on this, sGC stimulators are recommended for use in PAH in people not receiving PDE5is. That stated, the exact role they should play in treatment algorithms requires further head‐to‐head and treatment‐naive studies. Given their contra‐indication with PDE5is and similar positioning in treatment pathways to these agents, patient‐specific factors including the balance of evidence for specific PAH aetiologies and any history of adverse effects should be considered when deciding between these agents. The RESPITE study should add further granularity to this decision‐making process. </p> <p>For PH associated with left heart disease, there is currently no evidence to support their use. </p> <p>In inoperable or recurrent CTEPH, sGC stimulators can improve exercise capacity and WHO functional class whilst reducing mean pulmonary pressures. sGC stimulators should be used in people with inoperable or recurrent CTEPH as a second line treatment to endarterectomy only. CTEPH should always be considered a surgically curable condition before reviewing medical therapy. </p> <p>Data trends towards reduced mortality in both PAH and CTEPH; however, no significant findings have yet been made. Further information is also required regarding the significance of serious adverse events. There is also currently no evidence supporting the use of sGC stimulators in children. </p> </section> <h3 class="title" id="CD011205-sec-0080">Implications for research</h3> <section id="CD011205-sec-0080"> <p>This meta‐analysis partially answers the question of the utility of sGC stimulators in PH, specifically regarding PAH, inoperable or recurrent CTEPH and left heart disease. Further trials are required to evaluate their use in other PH forms, other population groups such as children, and to clarify positioning in treatment algorithms. sGC stimulators' effects on mortality require further investigation in the long term. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011205-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011205-sec-0015"></div> <div class="table" id="CD011205-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings table</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Riociguat compared to placebo for pulmonary hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> Adults (&gt;18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)<br/> <b>Setting:</b> Randomised controlled trials of 16 weeks duration or less<br/> <b>Intervention:</b> Ricociguat<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Aetiology</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Ricociguat</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Change in Exercise Capacity (6MWD)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in Exercise Capacity (6MWD) ‐ Group 1: PAH in the intervention group was <b>12 m higher</b> (45 fewer to 69 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in Exercise Capacity (6MWD) ‐ Group 4: CTEPH in the intervention group was <b>45 m higher</b> (24 m more to 66 m more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note small effect size</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.29</b> <br/> (0.05 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.57</b> <br/> (0.42 to 50.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (2 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.30</b> <br/> (0.05 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Improvement in WHO Functional Class</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235 per 1000<br/> (128 to 315) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.53</b> <br/> (0.87 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (102 to 325) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b> <br/> (0.41 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 per 1000<br/> (201 to 490) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.80</b> <br/> (1.43 to 5.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Serious Adverse Events (Participants with one or more event)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<br/> (49 to 472) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.93</b> <br/> (0.22 to 3.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335 per 1000<br/> (201 to 502) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.56</b> <br/> (0.78 to 3.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/> (110 to 326) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.29</b> <br/> (0.65 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CTEPH:</b> Chronic Thromboembolic Pulmonary Hypertension <b>CI:</b> Confidence interval; <b>PAH:</b> Pulmonary arterial hypertension; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>WHO:</b> World Health Organization; <b>6MWD:</b> 6‐minute walk distance </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to indirectness (variable treatment regimens in included studies) </p> <p><sup>2</sup> Downgraded due to imprecision in outcome </p> <p><sup>3</sup> Downgraded due to heterogeneity (I² &gt; 50%) </p> <p><sup>4</sup> Note that the pooled outcome includes data from trials with contra‐indicated drugs (PDE5is) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011205-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011205-sec-0016">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011205-sec-0098">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011205-sec-0016"></div> <section id="CD011205-sec-0017"> <h3 class="title" id="CD011205-sec-0017">Description of the condition</h3> <p>Pulmonary hypertension (PH) is an important cause of morbidity and mortality, affecting up to 100 million people worldwide (<a href="./references#CD011205-bbs2-0059" title="SchermulyRT , JanssenW , WeissmannN , StaschJP , GrimmingerF , GhofraniHA . Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs2011;20(4):567‐76. ">Schermuly 2011</a>). It leads to a substantial loss of exercise capacity, as well as causing right ventricular overload, resulting in heart failure and early mortality. Current three year survival ranges from 58.2% to 73.3% (<a href="./references#CD011205-bbs2-0045" title="LingY , JohnsonMK , KielyDG , CondliffeR , ElliotCA , GibbsJS . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2012;186(8):790‐6. ">Ling 2012</a>). </p> <p>PH is diagnosed when resting mean pulmonary arterial pressure (pPA) is 25 mmHg or more at cardiac catheterization. The clinical phenotype includes dyspnoea (<a href="#CD011205-tbl-0002">Table 1</a>), syncope (<a href="#CD011205-tbl-0002">Table 1</a>), chest pain and fatigue, whilst examination may reveal cyanosis (<a href="#CD011205-tbl-0002">Table 1</a>), right ventricular heave, a loud pulmonary second heart sound, and in late disease, signs of right heart failure. The degree of physical limitation can be categorised by the 6‐minute walking distance (6MWD) or the results at cardiopulmonary exercise testing (<a href="./references#CD011205-bbs2-0048" title="MiyamotoS , NagayaN , SatohT , KyotaniS , SakamakiF , FujitaM , et al. Clinical correlates and prognostic significance of six‐minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine2000;161(2 Pt 1):487‐92. ">Miyamoto 2000</a>; <a href="./references#CD011205-bbs2-0024" title="AbumehdiMR , WardleAJ , NazzalR , CharalampopoulosA , Schulze‐NeickI , DerrickG , et al. Feasibility and safety of cardiopulmonary exercise testing in children with pulmonary hypertension. Cardiology in the Young2015;26(6):1144‐50. ">Abumehdi 2015</a>). PH symptoms are classified clinically according to the World Health Organization (WHO) functional class system (1 = no limitation, 4 = symptomatic at rest; <a href="./references#CD011205-bbs2-0032" title="GalièN , CorrisPA , FrostA , GirgisRE , GrantonJ , JingZC , et al. Updated treatment algorithm of pulmonary arterial hypertension. Journal of the American College of Cardiology2013;62(25 Suppl):D60‐72. ">Galiè 2013</a>). </p> <div class="table" id="CD011205-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of Terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cyanosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A blue discolouration of the skin secondary to poor circulation or blood oxygenation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty in breathing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient loss of consciousness and posture due to inadequate perfusion of the brain</p> </td> </tr> </tbody> </table> </div> <p>PH is divided into five aetiological categories according to the WHO criteria (<a href="./references#CD011205-bbs2-0062" title="SimonneauG , GatzoulisMA , AdatiaI , CelermajerD , DentonC , GhofraniA , et al. Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology2013;62(25 Suppl):D34‐41. ">Simonneau 2013b</a>), of which three categories are relevant to our review. Group 1 is pulmonary arterial hypertension (PAH). This is subdivided further into groups including PH associated with congenital heart disease (CHD), connective tissue disease, heritable PH and, the most common group, idiopathic PH. PAH treatment options include calcium channel blockers, phosphodiesterase‐V inhibitors (PDE5is), dual‐endothelin receptor antagonists and prostanoids. More recently soluble guanylate cyclase (sGC) stimulators have gained approval. Despite this, annual mortality remains 15% (<a href="./references#CD011205-bbs2-0066" title="ThenappanT , ShahSJ , RichS , TianL , ArcherSL , Gomberg‐MaitlandM . Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. European Respiratory Journal2010;35(5):1079‐87. ">Thenappan 2010</a>). Group 2 is PH associated with left heart disease, the most common form of PH worldwide, affecting up to 30% of people with heart failure. There is no proven treatment that specifically targets PH in this condition (<a href="./references#CD011205-bbs2-0029" title="DamyT , GoodeKM , Kallvikbacka‐BennettA , LewinterC , HobkirkJ , NikitinNP , et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. European Heart Journal2010;31(18):2280‐90. ">Damy 2010</a>). The other major class relevant to this review is group 4, chronic thromboembolic PH (CTEPH). This entails vessel occlusion secondary to thromboses or emboli, alongside a vasoconstrictive component, which leads to significant increases in vascular resistance. PH is associated with poorer outcomes in pulmonary embolism unless early diagnosis is made (<a href="./references#CD011205-bbs2-0057" title="RiedelM , StanekV , WidimskyJ , PrerovskyI . Longterm follow‐up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest1982;81(2):151‐8. ">Riedel 1982</a>). Pulmonary endartectomy (PEA) is the gold‐standard management for CTEPH. However, up to 63% of candidates are ineligible for surgery due to co‐morbidities, unsuitable morphology, surgical centre access or declining consent (<a href="./references#CD011205-bbs2-0046" title="MayerE , JenkinsD , LindnerJ , D'ArminiA , KloekJ , MeynsB , et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Journal of Thoracic and Cardiovascular Surgery2011;141(3):702‐10. ">Mayer 2011</a>). Balloon angioplasty has also been used with some effect for inoperable cases, although there is currently no randomised data underlying this (<a href="./references#CD011205-bbs2-0065" title="TatebeS , SugimuraK , AokiT , MiuraM , NochiokaK , YaoitaN , et al. Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation Journal: official journal of the Japanese Circulation Society2016;80(4):980‐8. ">Tatebe 2016</a>). Furthermore, the condition either recurs or is refractory to surgery in 5% to 35% of cases (<a href="./references#CD011205-bbs2-0067" title="ThistlethwaitePA , KempA , DuL , MadaniMM , JamiesonSW . Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery2006;131(2):307‐13. ">Thistlesthwaite 2006</a>; <a href="./references#CD011205-bbs2-0028" title="BondermanD , Skoro‐SajerN , JakowitschJ , AdlbrechtC , DunklerD , TaghaviS , et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation2007;115(16):2153‐8. ">Bonderman 2007</a>). This leaves substantial unmet medical need. </p> </section> <section id="CD011205-sec-0018"> <h3 class="title" id="CD011205-sec-0018">Description of the intervention</h3> <p>As our understanding of PH has evolved, numerous medications have been developed with the hope of improving clinical outcomes (<a href="./references#CD011205-bbs2-0032" title="GalièN , CorrisPA , FrostA , GirgisRE , GrantonJ , JingZC , et al. Updated treatment algorithm of pulmonary arterial hypertension. Journal of the American College of Cardiology2013;62(25 Suppl):D60‐72. ">Galiè 2013</a>). Historically calcium channel blockers are the first line treatment but only for those responding positively at vaso reactivity tests. Prostanoids were the first real breakthrough, and are still widely considered the gold standard due to their superior efficacy but have a significant side effect profile. However, the most common form requires continuous intravenous infusion, with associated complications limiting utility. More recent developments include both selective and dual endothelin receptor antagonists (e.g. ambrisentan, bosentan, macitentan) and phosphodiesterase‐V inhibitors (e.g. sildenafil, tadalafil) (<a href="./references#CD011205-bbs2-0069" title="WardleA , TullohR . Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors. Pediatric Cardiology2013;34(2):213‐9. ">Wardle 2013b</a>). The decision of which PAH regimen to use is determined by WHO functional class amongst other factors (<a href="./references#CD011205-bbs2-0032" title="GalièN , CorrisPA , FrostA , GirgisRE , GrantonJ , JingZC , et al. Updated treatment algorithm of pulmonary arterial hypertension. Journal of the American College of Cardiology2013;62(25 Suppl):D60‐72. ">Galiè 2013</a>). Studies have suggested and it is widely accepted that 6MWD greater than 400 m is associated with improved survival; however, this is yet to be proved. There is a lack of randomised controlled trial (RCT) data in paediatric groups overall, meaning drug treatment is based largely upon adult evidence (<a href="./references#CD011205-bbs2-0041" title="IvyDD , AbmanSH , BarstRJ , BergerRM , BonnetD , FlemingTR , et al. Pediatric pulmonary hypertension. Journal of the American College of Cardiology2013;62(25 Suppl):D117‐26. ">Ivy 2013</a>). </p> <p>In 2013, the Food and Drug Administration (FDA) approved riociguat, a sGC stimulator, the first in a novel class of PH treatments (<a href="./references#CD011205-bbs2-0037" title="GuhaM . First‐in‐class guanylate cyclase stimulator approved for PAH. Nature Biotechnology2013;31(12):1064. ">Guha 2013</a>), which now also has European approval (<a href="./references#CD011205-bbs2-0031" title="DowdallM . Riociguat recommended by CHMP for approval in the WU for use in two forms of pulmonary hypertension. Future Cardiology2014;10(2):163. ">Dowdall 2014</a>). This license pertained not only to PAH, but to CTEPH also. This makes sGC stimulators the first specific treatment for inoperable or recurrent CTEPH. Inoperable CTEPH is that determined to be unsuitable for PEA by a multi‐disciplinary surgical team, whilst recurrent CTEPH is that occurring after PEA has been performed. Medical therapy is not intended as a replacement for surgery in people suitable for PEA (<a href="./references#CD011205-bbs2-0025" title="ArcherSL . Riociguat for pulmonary hypertension ‐ a glass half full. New England Journal of Medicine2013;369(4):386‐8. ">Archer 2013</a>) and any attempt at this should be discouraged. Furthermore, surgery should not be delayed for trials of medical therapy (<a href="./references#CD011205-bbs2-0044" title="KeoghAM , MayerE , BenzaRL , CorrisP , DartevellePG , FrostAE , et al. Interventional and surgical modalities of treatment in pulmonary hypertension. Journal of the American College of Cardiology2009;54(1 Suppl):S67‐77. ">Keogh 2009</a>). </p> <p>When considering the clinical use of riociguat, the price implications are still poorly defined, but should be in line with rival PAH agents at GBP 25,931 per year (<a href="./references#CD011205-bbs2-0027" title="BayerPharmaceuticals . 2014 Price List. www.bayer.co.uk/html/pdf/Pharma/190614_Official_List_Prices.pdf (accessed 7 July 2014). ">Bayer 2014</a>). Riociguat comes in the form of an oral tablet (up to 2.5 mg as tolerated), taken three times daily to aid patient compliance. </p> </section> <section id="CD011205-sec-0019"> <h3 class="title" id="CD011205-sec-0019">How the intervention might work</h3> <p>sGC stimulators are a novel class of PH medication that manipulate endogenous mechanisms controlling pulmonary pressures. In normal physiology, the body regulates pulmonary flow, and therefore resistance, through a unique set of endocrine and paracrine effectors. One of these is the ventilation‐induced release of endothelial nitric oxide (NO) to stimulate vasodilatation via smooth muscle cells. NO does this by stimulating sGC to produce cyclic guanosine monophosphate (cGMP). cGMP activates kinases that lead to vasodilatation and the inhibition of inflammation and thrombosis (<a href="./references#CD011205-bbs2-0030" title="DenningerJW , MarlettaMA . Guanylate cyclase and the NO/cGMP signalling pathway. Biochimica et Biophysica Acta1999;1411(2‐3):334‐50. ">Denninger 1999</a>; <a href="./references#CD011205-bbs2-0034" title="GhofraniHA , Pepke‐ZabaJ , BarberaJA , ChannickR , KeoghAM , Gomez‐SanchezMA , et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. Journal of the American College of Cardiology2004;43(12 Suppl):68S‐72S. ">Ghofrani 2004</a>). In addition, the potential for increasing cGMP as a therapeutic target for pulmonary vasodilatation is demonstrated by PDE5is (<a href="./references#CD011205-bbs2-0068" title="WardleAJ , WardleR , LuytK , TullohR . The utility of sildenafil in pulmonary arterial hypertension: a focus on bronchopulmonary dysplasia. Archives of Disease in Childhood2013;98(9):613‐7. ">Wardle 2013a</a>; <a href="./references#CD011205-bbs2-0069" title="WardleA , TullohR . Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors. Pediatric Cardiology2013;34(2):213‐9. ">Wardle 2013b</a>). However, it is hoped that sGC stimulators may display greater efficacy than PDE5is due to their independence from NO bioavailability, relative lack of adverse effects, and actions as a NO sGC sensitiser and stimulator (<a href="./references#CD011205-bbs2-0064" title="StaschJP , PacherP , EvgenovOV . Guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation2011;123(20):2263‐73. ">Stasch 2011</a>). </p> </section> <section id="CD011205-sec-0020"> <h3 class="title" id="CD011205-sec-0020">Why it is important to do this review</h3> <p>There is already significant controversy over the most effective medication for PAH and this will deepen with the introduction of sGC stimulators. It also remains to be seen how sGC stimulators should be used in the context of CTEPH — whether they are a replacement for PEA in people at high surgical risk, an adjunct, or a measure of last resort. By collating the evidence of these agents in PH it is hoped that we will address these issues whilst also increasing the evidence base for adverse effects — an area still lacking sufficient data. Finally, this work will also act as a protocol capable of being repeated in the future as the evidence base for these agents continues to evolve, and therefore begin to act as basis for comparison between different available treatments. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011205-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011205-sec-0021">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011205-sec-0103">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011205-sec-0021"></div> <p>To evaluate the efficacy of sGC stimulators in pulmonary hypertension.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011205-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011205-sec-0022">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011205-sec-0104">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011205-sec-0022"></div> <section id="CD011205-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011205-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). This included studies reported as full‐text, abstract only, and unpublished data. We excluded all studies not conforming to the RCT format. </p> </section> <section id="CD011205-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included both adults and children (0 to 18 years) diagnosed with PH.</p> </section> <section id="CD011205-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing sGC stimulators with usual care and placebo. We also sought to compare head‐to‐head trials comparing different sGC stimulators as a separate comparison. We included the following co‐interventions. </p> <p> <ol id="CD011205-list-0001"> <li> <p>PDE5is</p> </li> <li> <p>Endothelin receptor antagonists</p> </li> <li> <p>Prostanoids</p> </li> <li> <p>Nitrates</p> </li> <li> <p>Calcium channel blockers</p> </li> <li> <p>Non‐PH specific medications including diuretics, anticoagulants and oxygen.</p> </li> </ol> </p> </section> <section id="CD011205-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD011205-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011205-list-0002"> <li> <p>Change in exercise capacity, measured by 6MWD.</p> </li> <li> <p>Mortality</p> </li> </ol> </p> </section> <section id="CD011205-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011205-list-0003"> <li> <p>Change in WHO functional class</p> </li> <li> <p>Time to clinical worsening</p> </li> <li> <p>Change in pulmonary arterial pressure (mmHg)</p> </li> <li> <p>Serious adverse events</p> </li> </ol> </p> <p>Reporting one of more of the outcomes listed here in the trial was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD011205-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011205-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We identified trials from searches of the following databases:</p> <p> <ul id="CD011205-list-0004"> <li> <p>The Cochrane Airways Group Register of Trials – all years.</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL), issue 2, 2016 (<i>The Cochrane Library).</i> </p> </li> <li> <p>MEDLINE (Ovid) 1950 to February 2016.</p> </li> <li> <p>EMBASE  (Ovid) 1974 to February 2016.</p> </li> <li> <p>Trials registries (<a href="http://www.clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> and the <a href="http://apps.who.int/trialsearch/" target="_blank">WHO trials portal</a>). </p> </li> </ul> </p> <p>The search strategy is detailed in <a href="./appendices#CD011205-sec-0084">Appendix 1</a>. We searched all databases from inception to present day, and did not impose any restriction on language or type of publication. We searched for conference abstracts and grey literature through the CENTRAL database. The search date was 12 February 2016. </p> </section> <section id="CD011205-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We searched relevant manufacturers' websites for trial information. </p> <p>We searched for errata or retractions from included studies published in full‐text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). This was done on 12 February 2016. </p> </section> </section> <section id="CD011205-sec-0033"> <h3 class="title" id="CD011205-sec-0033">Data collection and analysis</h3> <section id="CD011205-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MS and RW) independently screened titles and abstracts for inclusion and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. We retrieved all available full‐text study reports and publications, and two review authors (MS and RW) independently screened for inclusion or identified and recorded reasons for exclusion. We resolved any disagreement through discussion or, when required, through a third review author (AW). One final review author (RT) analysed the included and excluded texts to ensure uniform enforcement of the study protocol. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD011205-fig-0001">Figure 1</a>) and '<a href="./references#CD011205-sec-0097" title="">Characteristics of excluded studies</a>' table. </p> <div class="figure" id="CD011205-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study Selection Flow diagram." data-id="CD011205-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study Selection Flow diagram.</p> </div> </div> </div> </section> <section id="CD011205-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data which had been piloted on at least one study in the review. One review author (MS) extracted study characteristics from included studies and this was duplicated by a second review author (RW). We extracted the following study characteristics. </p> <p> <ol id="CD011205-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (MS and RW) independently extracted outcome data from included studies. We noted in the '<a href="./references#CD011205-sec-0096" title="">Characteristics of included studies</a>' table if outcome data were not reported in a usable way. We resolved disagreements by consensus or by involving a third review author (AW). One review author (AW) transferred data into the Review Manager (<a href="./references#CD011205-bbs2-0056" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2012</a>) file. We double‐checked that data was entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (RW) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD011205-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MS and RW) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011205-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreements by discussion or by involving another review author (AW or RT). We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD011205-list-0006"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>We graded each potential source of bias as 'high', 'low' or 'unclear' and provided a quote from the study report together with a justification for our judgment in the 'Risk of bias' table. We summarised risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different than for a patient‐reported pain scale). Where information on risk of bias was related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD011205-sec-0037"> <h5 class="title">Assesment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD011205-bbs2-0070" title="WardleAJ , TullohRMR . Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD011205] ">Wardle 2014</a>) and have reported any deviations from it in the "<a href="#CD011205-sec-0094">Differences between protocol and review</a>" section below. </p> </section> </section> <section id="CD011205-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as risk ratios and continuous data as the mean difference or standardised mean difference. We entered data as a scale with consistent direction of effect. Meta‐analyses were performed only where it was meaningful i.e. if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. Any skewed data is described in narrative using medians and interquartile ranges. Where multiple trial arms were reported in a single trial, we included only the relevant arms in the data set. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. When trials were taking measurements of treatment effect at different time points, we took the data point nearest to the predetermined set time point. Set time points included results at four weeks, 12 weeks, 26 weeks and 52 weeks post‐initiation of treatment. </p> </section> <section id="CD011205-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. The eligibility of non‐standard randomisation study designs was questioned and taken into account during subsequent analysis of bias. We excluded cross‐over study designs due to the large variability in PH disease course, the potential for previous treatment to modify future outcomes, and the risk of pharmacodynamic crossover. </p> </section> <section id="CD011205-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators and study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). When this was not possible, and the missing data was thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results using a sensitivity analysis<b>. </b> </p> </section> <section id="CD011205-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity amongst the trials in each of the analyses. When we identified substantial heterogeneity we reported it and explored possible causes using prespecified subgroup analyses.  </p> </section> <section id="CD011205-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had been able to pool more than 10 trials, we would have created a funnel plot to explore possible small study and publication biases. </p> </section> <section id="CD011205-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model throughout. We made this decision on the basis that the inherent heterogeneity of this population should not affect the outcome measures of interest in this work. </p> <section id="CD011205-sec-0044"> <h5 class="title">Summary of findings table</h5> <p>We created a 'Summary of findings' table aligned to the following outcomes:</p> <p> <ol id="CD011205-list-0007"> <li> <p>Change in exercise capacity, measured by 6MWD</p> </li> <li> <p>Mortality</p> </li> <li> <p>Change in WHO functional class</p> </li> <li> <p>Serious adverse events</p> </li> </ol> </p> <p>We used the eight GRADE considerations (risk of bias, inconsistency, indirectness, imprecision, publication bias, large effect, plausible confounding and dose response gradient) to assess the quality of evidence as it relates to the studies that contribute data to the relevant meta‐analysis. We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011205-bbs2-0038" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) using GRADEpro software (<a href="./references#CD011205-bbs2-0036" title="GRADE Working Group, McMaster. GRADEpro GDT. Version accessed 13 July 2016. Hamilton (ON): GRADE Working Group, McMaster, 2014. ">GRADEpro GDT</a>). All decisions to down‐grade or up‐grade the quality of studies is justified within footnotes and comments to aid the reader's understanding of the review as necessary. Data on 6MWD, mortality and change in WHO functional class was broken down according to PH classification group. </p> </section> </section> <section id="CD011205-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses.</p> <p> <ol id="CD011205-list-0008"> <li> <p>Dose (riociguat: less than 1 mg three times daily, 1 to 2.4 mg three times daily, or 2.5 mg or greater three times daily). <i>This was not performed due to inadequate data volumes and detail in results.</i> </p> </li> <li> <p>Frequency of medication administration. <i>All included studies employed the same frequency of administration.</i> </p> </li> <li> <p>Duration of treatment (&lt; 24 weeks or &gt; 24 weeks). <i>No studies exceeded 24 weeks.</i> </p> </li> <li> <p>WHO functional class. <i>There was inadequate study detail available to subgroup according to WHO functional class.</i> </p> </li> <li> <p>Combination with alternative PH therapies (phosphodiesterase‐V inhibitors, endothelin receptor antagonists, prostanoids, nitrates, calcium channel blockers, non‐PH specific medications including diuretics, anti‐coagulants and oxygen). <i>This was performed for exercise and serious adverse event outcomes.</i> </p> </li> <li> <p>Underlying aetiology of pulmonary hypertension, including WHO classification grouping and then subgrouping. <i>This was performed for exercise and serious adverse event outcomes.</i> </p> </li> </ol> </p> <p>We used the following outcomes in subgroup analyses.</p> <p> <ol id="CD011205-list-0009"> <li> <p>Change in 6MWD</p> </li> <li> <p>Serious adverse event</p> </li> </ol> </p> <p>During this, we applied the formal test for subgroup interactions in Review Manager 5 (<a href="./references#CD011205-bbs2-0056" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2012</a>). In addition to these subgroup analyses, we also analysed data together as a single complete set to allow subgroup analyses to infer causes of heterogeneity. </p> </section> <section id="CD011205-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out the following sensitivity analyses when appropriate.</p> <p> <ol id="CD011205-list-0010"> <li> <p>Selection bias i.e. RCT versus quasi‐RCT</p> </li> <li> <p>Performance and assessment bias e.g. blinding when applicable</p> </li> <li> <p>Attrition bias (rate of drop‐out less than 20% versus 20% or higher)</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011205-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011205-sec-0047"></div> <section id="CD011205-sec-0048"> <h3 class="title">Description of studies</h3> <p>See <a href="#CD011205-sec-0050">Included studies</a>; <a href="#CD011205-sec-0051">Excluded studies</a>. </p> <section id="CD011205-sec-0049"> <h4 class="title">Results of the search</h4> <p>The literature search identified 259 abstracts and titles. After applying the aforementioned inclusion and exclusion criteria, we identified five RCTs suitable for inclusion within this review (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). This process is summarised in a flow diagram (<a href="#CD011205-fig-0001">Figure 1</a>). Full text publications were obtained from the websites of the original source of publication. When studies were referenced more than once, data were combined in order to give as complete an interpretation as possible of available data. </p> </section> <section id="CD011205-sec-0050"> <h4 class="title">Included studies</h4> <p>All studies were randomised and controlled in a parallel design and their characteristics are summarised in <a href="#CD011205-tbl-0003">Table 2</a> and <a href="#CD011205-tbl-0004">Table 3</a>. </p> <div class="table" id="CD011205-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies summary</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PH Type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of Countries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number Completed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention Group PH Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control Group PH Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial Phase</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 2: left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2 mg three times daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IIb</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 2: left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat 0.5 mg, 1 mg, or 2 mg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IIa</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2 mg three times daily. People on stable sildenafil therapy at point of selection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo with sham titrations. People on stable sildenafil therapy at point of selection.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2.5 mg three times daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo with sham titrations.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2.5 mg three times daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo with sham titrations.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CTEPH:</b> Chronic Thromboembolic Pulmonary Hypertension; <b>PAH:</b> Pulmonary arterial hypertension </p> </div> </div> <div class="table" id="CD011205-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Parameters relevant to protocol studied</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in 6MWD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Worsening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious Adverse Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in mean PA pressure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>"1" = Primary outcome measure of study. "2" = Secondary outcome measure of study. "3" = Parameter measured but not explicitly as a primary or secondary outcome. "‐" = measure not included in study. </p> </div> </div> <p>Out of the five included studies, a total of 966 participants were randomised, with 874 of these participants completing the study; this is made up of <a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a> (202 randomised, 172 completed), <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a> (39 randomised, 37 completed), <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> (18 randomised, 17 completed), <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a> (445 randomised, 405 completed), and <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a> (262 randomised, 243 completed). Four of these were controlled against placebo only (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>). One study used stably managed sildenafil treatment in the control group as well the interventional group (<a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). All studies chose riociguat as their interventional agent. </p> <p>All participants were adults (&gt; 18 years old) and diagnosed with pulmonary hypertension. The aetiology of pulmonary hypertension varied and included PAH (<a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>), CTEPH (<a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>) and left‐sided heart failure (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>). </p> <p>6MWD was the primary outcome measure in two trials (<a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>). Change in pPA was the primary outcome in two studies (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>). Adverse events were the primary outcome in one study (<a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). Additional outcome measures included change in pulmonary vascular resistance, N‐terminal pro‐brain natriuretic peptide, WHO functional class, time to clinical worsening, Borg dyspnoea scale score, quality of life, haemodynamic and echocardiographic cardiac parameters and pharmacokinetics. </p> <p>Further details including dosing and baseline exercise capacity can be found in the '<a href="./references#CD011205-sec-0096" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD011205-sec-0051"> <h4 class="title">Excluded studies</h4> <p>Twenty‐four references were excluded, and the reasons for this are outlined in the '<a href="./references#CD011205-sec-0097" title="">Characteristics of excluded studies</a>' table. </p> </section> </section> <section id="CD011205-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD011205-sec-0053"> <h4 class="title">Allocation</h4> <p>All works reported are international, multicentre, double‐blind, randomised, placebo‐controlled trials (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). All studies utilised computer‐generated random numbers alongside adequate concealment of allocation. </p> </section> <section id="CD011205-sec-0054"> <h4 class="title">Blinding</h4> <p>All studies are self‐described as "double‐blinded". However, none of the studies provided further information on the blinding process, therefore all studies were judged to have an unclear risk of bias. </p> </section> <section id="CD011205-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>Details of dropouts and withdrawals were described by all studies. Two studies employed an intention‐to‐treat analysis (<a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>). Two studies employed a per‐protocol analysis (<a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). One study used a combination of intention‐to‐treat and per protocol analyses depending on the variable (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>). No study had a dropout rate exceeding 20%. The risk of bias is more completely described in the '<a href="./references#CD011205-sec-0096" title="">Characteristics of included studies</a>' tables and <a href="#CD011205-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD011205-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011205-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD011205-sec-0056"> <h4 class="title">Selective reporting</h4> <p>A low risk of reporting bias was found in four studies (<a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>), with outcomes reported in published works consistent with those stated in the protocols published beforehand. One study published all of the outcomes mentioned in the original protocol, as well as some further data not previously mentioned (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>). One study reported important outcomes for this meta‐analysis (6MWD and change in WHO functional class) as exploratory variables only (<a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> also had a further extension study that was stopped early. There is no data on this study that is publicly available and therefore this represents a potentially significant source of bias. </p> </section> <section id="CD011205-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>It should be noted that all included studies were sponsored by the drug manufacturer.</p> </section> </section> <section id="CD011205-sec-0058"> <h3 class="title" id="CD011205-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD011205-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings table</a> </p> <section id="CD011205-sec-0059"> <h4 class="title">Riociguat versus placebo</h4> <p>On theoretical discussion and preliminary analysis it was agreed that PH pathophysiology varies widely and is likely to drive heterogeneity in results. As such, we have presented all results broken down according to PH diagnostic classification. Any further analyses that were run are commented on separately within the text but not within forest plots. It should be noted that these other subgroups do not take into account PH aetiology. </p> <p>Throughout all studies there were no differences in the daily frequency of dose administration reported. All reported trials were of less than 24 weeks total duration and therefore no further subgroup analysis was required. Futher subgroup analysis is detailed alongside pooled data analysis in the appropriate results. </p> <section id="CD011205-sec-0060"> <h5 class="title">Primary outcomes</h5> <section id="CD011205-sec-0061"> <h6 class="title">Exercise capacity</h6> <p>Four trials of 819 participants assessed change from baseline in 6MWD (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). That stated, only <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>, <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a> and <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> presented data suitable for pooling to the appropriate outcome. This totaled 659 participants. The pooled data demonstrate a mean difference (MD) versus placebo of 30.13 m (95% CI 5.29 to 54.96; participants = 659; studies = 3; I² = 64%) with potential substantial heterogeneity (<a href="./references#CD011205-fig-0003" title="">Analysis 1.1</a>). All studies used dose titration of riociguat up to 2.5 mg three times daily and so further subgroup analysis of dosing was not applicable. Authors were contacted for data regarding WHO functional class at baseline and changes in exercise capacity; unfortunately no further data was obtained. Only one trial explicitly dealt with a combination of riociguat with other named PH therapies (<a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). Data were presented according to PH aetiology. </p> <p>When looking at the PAH group alone, MD was 12 m (95% CI −44.92 to 68.75; participants = 398; studies = 2; I² = 77%). </p> <p><a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a> presented 6MWD change data relative to the control group only and therefore was not suitable for pooled analysis. This trial reported a placebo‐corrected least‐squares MD of 10 m (95% CI −18 to 39; P = 0.48; participants = 202) in favour of riociguat 2 mg. </p> <p>Looking at CTEPH alone, the MD was 45 m (95% CI 23.87 to 66.13; participants = 261; studies = 1; I² = 0%). </p> </section> <section id="CD011205-sec-0062"> <h6 class="title">Mortality</h6> <p>Fourteen deaths were reported from a total 899 participants in all trials (<a href="./references#CD011205-fig-0004" title="">Analysis 1.2</a>). The pooled analysis shows no significant difference in mortality (Peto OR 0.57, 95% CI 0.18 to 1.80; participants = 899; studies = 5; I² = 22%) and did not display significant heterogeneity. </p> </section> </section> <section id="CD011205-sec-0063"> <h5 class="title">Secondary outcomes</h5> <section id="CD011205-sec-0064"> <h6 class="title">Change in WHO functional class</h6> <p>Four studies (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>), including 858 participants, measured changes in exercise capacity according to the WHO functional class system (<a href="./references#CD011205-fig-0005" title="">Analysis 1.3</a>). Pooled analysis shows an odds ratio of 1.53 (95% CI 0.87 to 2.72; participants = 858; studies = 4; I² = 49%) in favour of riociguat for the improvement of WHO functional class. I² for this outcome is 49% and could represent substantial heterogeneity. </p> </section> <section id="CD011205-sec-0065"> <h6 class="title">Time to clinical worsening</h6> <p>Three studies (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>), including 842 participants, reported events of clinical worsening during the trial period (<a href="./references#CD011205-fig-0006" title="">Analysis 1.4</a>). Pooled analysis shows an OR of 0.45 (95% CI 0.17 to 1.14; participants = 842; studies = 3; I² = 54%) towards clinical worsening in the placebo group. I² for this outcome is 54% and could represent substantial heterogeneity. </p> </section> <section id="CD011205-sec-0066"> <h6 class="title">Serious adverse events</h6> <p>Due to variability in reporting, only serious adverse events were analysed in this review and this has been measured as the number of people experiencing one or more events rather than total number of events. From 818 participants, pooled data indicates an OR of 1.12 (95% CI 0.66 to 1.90; participants = 818; studies = 5; I² = 39%) for serious adverse events being recorded between placebo and riociguat groups, with potential for moderate heterogeneity (<a href="./references#CD011205-fig-0007" title="">Analysis 1.5</a>). </p> <p>Two studies dealt with participants with PAH (<a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>). The pooled data did not show a difference in serious adverse events (OR 0.93, 95% CI 0.22 to 3.83; participants = 398; studies = 2; I² = 53%) and potential substantial heterogeneity. We believe this is likely due to the use of PDE5is in <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a>. This study presented data descriptively due to the small cohort size, and did not show a difference in serious adverse events. However, caution should be taken when reviewing these results as the longer‐term extension of the trial was stopped due to a high incidence of adverse events. Two studies analysed effects in PH associated with left heart disease (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>). This showed an odds ratio of 1.56 (95% CI 0.78 to 3.13; participants = 159; studies = 2; I² = 0%) without evidence of heterogeneity. One study analysed effects in CTEPH: this reported an odds ratio of 1.29 (95% CI 0.65 to 2.56; participants = 261; studies = 1; I² = 0%). Of note, 2% of riociguat recipients developed haemoptysis in this study. </p> </section> <section id="CD011205-sec-0067"> <h6 class="title">Change in pulmonary artery pressure</h6> <p>Four studies (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a>; <a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>), involving 744 participants, directly measured changes in pulmonary artery pressure at baseline and study endpoint (<a href="./references#CD011205-fig-0008" title="">Analysis 1.6</a>). Pooled analysis shows a MD of −2.77 mmHg (95% CI −4.96 to −0.58; participants = 744; studies = 3; I² = 49%) in the riociguat group versus placebo. I² for this outcome is 49% and could represent substantial heterogeneity. </p> <p><a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a> presented pulmonary artery pressure relative to the control group only and therefore was not suitable for pooled analysis. This trial reported a mean treatment difference of −8.0 mmHg (95% CI −15.5 to −0.6; P = 0.04; participants = 36) in favour of riociguat 2 mg. </p> <p><a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> measured pulmonary artery pressure as an exploratory variable but did not publish relevant data. The study does, however, state that there were "no between‐group differences". </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011205-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011205-sec-0068">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011205-sec-0112">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011205-sec-0068"></div> <section id="CD011205-sec-0069"> <h3 class="title" id="CD011205-sec-0069">Summary of main results</h3> <p>Pooled data show that sGC stimulators can increase exercise capacity (6MWD) and cause reductions in pulmonary artery pressure in adults with PH. However, the significant levels of statistical heterogeneity should be noted when reviewing pooled results and broadly speaking, treatment effects should be looked at with respect to PH aetiology. There is currently no evidence for use in children and studies assessing use in left heart disease have been negative thus far. Furthermore, evidence suggests that use in the context of nitrates or PDE5is should be avoided and there is no evidence for the use of riociguat in people suitable for PEA. </p> <section id="CD011205-sec-0070"> <h4 class="title">PH Group 1: PAH</h4> <p>PAH is an important cause of mortality. Until recently treatments that decrease pulmonary pressures and improve exercise capacity were restricted to prostanoids, endothelin receptor antagonists and phosphodiesterase inhibitors. This systematic review supports the addition of sGC stimulators to improve exercise capacity. This is true for those not receiving PDE5is only and that is how results are reviewed. sGC stimulators improve 6MWD, a marker of prognosis (<a href="./references#CD011205-bbs2-0047" title="McLaughlinVV , GaineSP , HowardLS , LeuchteHH , MathierMA , MehtaS . Treatment goals of pulmonary hypertension. Journal of the American College of Cardiology2013;62(25 Suppl):D73‐81. ">McLaughlin 2013</a>), by 30 m when taken three times a day. This is very similar to the 28 m achieved with the addition of sildenafil to people receiving prostanoids (<a href="./references#CD011205-bbs2-0061" title="SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE , et al. Addition of sildenafil to long term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomised trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>). However, this is yet to translate into improvements in mortality. Prostanoids have shown mortality benefit at 6MWD improvement of 47 metres in idiopathic PAH (<a href="./references#CD011205-bbs2-0026" title="BarstRJ , RubinLJ , LongWA , McGoonMD , RichS , BadeschDB . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The New England Journal of Medicine1996;334(5):296‐302. ">Barst 1996</a>). Riociguat shows a similar improvement in 6MWD, especially in the 1 year extension study (+ 48 m, SD 72 m) (<a href="./references#CD011205-bbs2-0058" title="RubinL , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): 1‐year results from the PATENT‐2 long‐term extension study [Abstract]. Chest. 2013; Vol. 144, issue 4 Meeting Abstracts:1024A. ">Rubin 2013</a>), but is yet to show associated mortality benefit. This same group, excluding PDE5is, showed improvements in clinical worsening, WHO functional class and pulmonary artery pressures. </p> <p>The above results have been achieved without clear evidence of harm in treatment‐naive participants, although the occurrence of haemoptysis means it is now a relative contraindication to treatment. PAH combination treatment is becoming increasingly common and often considered desirable as emphasised by its superiority in the recent Ambition study (<a href="./references#CD011205-bbs2-0033" title="GalièN . The AMBITION study: design and results. European Respiratory Journal2014;44(Suppl.58):2916. ">Galiè 2014</a>). Riociguat has shown this to be possible with people on stable prostanoid or endothelin receptor antagonist therapy. There is currently no data on which combination of these agents may be most desirable. However, riociguat cannot be combined with PDE5is. <a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> showed that the long‐term addition of riociguat to people already on stable sildenafil is potentially dangerous with elevated incidences of adverse events, serious adverse events including hypotension, participant dropout and mortality. It has therefore been recommended that riociguat be contraindicated in people already receiving sildenafil or any other PDE5i. It should be noted that these studies are largely based upon idiopathic PAH and results may differ between PAH subgroups </p> </section> <section id="CD011205-sec-0071"> <h4 class="title">PH Group 2: Left heart disease</h4> <p>PH associated with heart failure with preserved or reduced ejection fraction is an important cause of mortality and morbidity in a very large and important patient group, affecting up to 30% of people with reduced ejection fraction (<a href="./references#CD011205-bbs2-0029" title="DamyT , GoodeKM , Kallvikbacka‐BennettA , LewinterC , HobkirkJ , NikitinNP , et al. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. European Heart Journal2010;31(18):2280‐90. ">Damy 2010</a>). That acknowledged, there remains controversy on how best to manage PH in this setting. Current treatment includes optimisation of heart failure medication including beta‐blockers and angiotensin‐converting enzyme inhibitors, the use of diuretics for careful fluid management and, when appropriate, biventricular pacing. There has been some investigation into the use of PAH therapies such as PDE5is in this setting but no agent has yet to demonstrate adequate efficacy for widescale use. </p> <p>Thus far, two trials have been completed on the use of riociguat in left heart disease‐associated PH (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>; <a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>). This included left ventricular systolic dysfunction (<a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a>) and preserved left ventricular ejection fraction heart failure (<a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a>). The results from these works do not show benefit due to the addition of riociguat in terms of exercise capacity or mortality and both miss their primary endpoint of achieving a reduction in PAP. These studies do report favourable haemodynamics (e.g. systemic vascular resistance, cardiac index, pulmonary vascular resistance) and improvements in quality of life scales, but do not reach the primary outcomes of the studies. Based on this, there is currently no evidence to support the introduction of sGC stimulators to this form of PH. </p> </section> <section id="CD011205-sec-0072"> <h4 class="title">PH Group 4: CTEPH</h4> <p>CTEPH is an important cause of mortality with limited treatment options. Gold‐standard treatment is PEA; however, in a group of patients this is either ineffective (recurrent CTEPH) or not feasible (inoperable CTEPH). Before riociguat's approval, management for these people was supportive and held a poor prognosis. The only other pharmacological intervention investigated has been bosentan, and despite reducing pulmonary artery pressures, it did not improve 6MWD over 16 weeks (<a href="./references#CD011205-bbs2-0042" title="JaisX , D'ArminiAM , JansaP , TorbickiA , DelcroixM , GhofraniHA . Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT(Bosentan effects in iNopErable forms of chronIc thromboembolic pulmonary hypertension), a randomized, placebo‐controlled trial. Journal of the American College of Cardiology2008;52(25):2127‐34. ">Jais 2008</a>). </p> <p>Riociguat has been evaluated in recurrent and inoperable CTEPH, and it is only in these groups that it can be recommended. In this setting, riociguat improves exercise tolerance and WHO functional class whilst reducing the incidence of clinical worsening and lowering pulmonary artery pressures. Evidence regarding serious adverse events remains inconclusive. Current evidence has not been designed to demonstrate an effect on mortality. That stated, the improvements in pulmonary haemodynamics achieved are significant, and higher pressures are a proven marker of poor prognosis (<a href="./references#CD011205-bbs2-0043" title="JamiesonSW , KapelanskiDP , SakakibaraN , ManeckeGR , ThistlethwaitePA , KerrKM , et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Annals of Thoracic Surgery2003;76(5):1462‐4. ">Jamieson 2003</a>). There is no evidence for the use of riociguat in CTEPH suitable for PEA. CTEPH should be considered a surgically curable condition before reviewing medical therapy. PEA remains the gold standard treatment for CTEPH as it not only improves haemodynamics and exercise capacity, but also has a demonstrable impact on survival (<a href="./references#CD011205-bbs2-0060" title="ScholzelBE , PostMC , Thijs PlokkerHW , SnijderRJ . Clinical worsening during long‐term follow‐up in inoperable chronic thromboembolic pulmonary hypertension. Lung2012;190(2):161‐7. ">Scholzel 2012</a>). As such, people with CTEPH who are potential PEA candidates should still be assessed at a centre capable of achieving this for complete exclusion of a PEA strategy before the consideration of riociguat. </p> </section> </section> <section id="CD011205-sec-0073"> <h3 class="title" id="CD011205-sec-0073">Overall completeness and applicability of evidence</h3> <p>All studies in this review collected data on one of the stated primary outcomes of this work (6MWD or mortality). All relevant participants, interventions and outcomes have been investigated. Overall, the evidence collected is highly applicable to this review. The evidence demonstrates that sGC stimulators have an important utility in PH. That stated, further data looking at different PH subgroups is required for a more complete guide as to their utility. </p> <p>Since the publication of initial PATENT and CHEST trials both have been subject to open‐label extension. In PATENT‐2 people receiving either monotherapy or combination with endothelin receptor antagonists or prostanoids showed sustained improvements in 6MWD, WHO‐FC, brain natriuretic peptide and survival at two years (<a href="./references#CD011205-bbs2-0035" title="GhofraniHA , GrimmingerF , GrünigE , HuangY , JansaP , JingZC , et al. Predictors of long‐term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT‐2 open‐label, randomised, long‐term extension trial. The Lancet Respiratory Medicine2016;4(5):361‐71. ">Ghofrani 2016</a>). CHEST‐2 showed overall survival of 93% and clinical worsening‐free survival of 82% at two years (<a href="./references#CD011205-bbs2-0063" title="SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , JansaP , KimNH , et al. Predictors of long‐term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST‐2 open‐label, randomised, long‐term extension trial. The Lancet Respiratory Medicine2016;4(5):372‐80. ">Simonneau 2016</a>). Both studies add weight to the notion of long‐term use of sGC‐stimulators. </p> </section> <section id="CD011205-sec-0074"> <h3 class="title" id="CD011205-sec-0074">Quality of the evidence</h3> <p>All studies included in this meta‐analysis were parallel, double‐blind, RCTs. Trials reported data using a mixture of per protocol and intention‐to‐treat analyses. The quality of the current evidence can be considered to be low overall (one high quality outcome, two moderate quality outcomes and eight low or very low quality outcomes). Downgrades were associated with imprecision and indirectness within the evidence base and this was sometimes associated with heterogeneity as explored more fully in <a href="./full#CD011205-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD011205-sec-0075"> <h3 class="title" id="CD011205-sec-0075">Potential biases in the review process</h3> <p>There are no known biases to disclose in the implementation of this review. It should be noted that all works included in this review were, however, sponsored by the pharmaceuticals company that launched the agent. </p> </section> <section id="CD011205-sec-0076"> <h3 class="title" id="CD011205-sec-0076">Agreements and disagreements with other studies or reviews</h3> <p>At the time of writing, this is the only known meta‐analysis of data on the use of sGC stimulators in PH. Published collative work so far has been in the form of literature reviews and editorials (<a href="./references#CD011205-bbs2-0025" title="ArcherSL . Riociguat for pulmonary hypertension ‐ a glass half full. New England Journal of Medicine2013;369(4):386‐8. ">Archer 2013</a>; <a href="./references#CD011205-bbs2-0039" title="HoeperMM . Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension. European Respiratory Review2015;24(136):272‐82. ">Hoeper 2015</a>; <a href="./references#CD011205-bbs2-0040" title="HumbertM , GhofraniHA . The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax2016;71(1):73‐83. ">Humbert 2015</a>). These generally advocate the use of sGC stimulators in inoperable or recurrent CTEPH and in adults with PAH. The findings of this analysis are in agreement with these works. </p> <section id="CD011205-sec-0077"> <h4 class="title">Ongoing and future research</h4> <p>A wide scope remains to investigate the role of sGC stimulators in PAH and CTEPH amongst other conditions. This is demonstrated by the ongoing long‐term extension studies PATENT‐2 (<a href="./references#CD011205-bbs2-0050" title="Bayer . Long‐term extension study in patients with pulmonary arterial hypertension (PATENT‐2). https://clinicaltrials.gov/ct2/show/NCT00863681 (accessed 13 July 2015). ">NCT00863681</a>) and CHEST‐2 (<a href="./references#CD011205-bbs2-0051" title="Bayer . Long‐term extension study in patients with chronic thromboembolic pulmonary hypertension (CHEST‐2). https://clinicaltrials.gov/ct2/show/NCT00910429 (accessed 13 July 2015). ">NCT00910429</a>). Furthermore, there is currently an ongoing recruitment process for an uncontrolled open‐label phase 3b investigation into the use of riociguat in people with PAH who are negative responders to phosphodiesterase‐V inhibitors (RESPITE; <a href="./references#CD011205-bbs2-0052" title="Bayer . Riociguat clinical effects studied in patients with insufficient treatment response to phosphodiesterase‐5 inhibitor (RESPITE). https://clinicaltrials.gov/ct2/show/NCT02007629 (accessed 13 July 2015). ">NCT02007629</a>). This study will allow a cross‐over insight into the effects of sildenafil and riociguat. </p> <p>The efficacy and safety of riociguat in other forms of PH is also being investigated. This includes people with PH associated with COPD (<a href="./references#CD011205-bbs2-0049" title="Bayer . Single dose study in patients with chronic obstructive pulmonary disease (COPD) associated pulmonary hypertension. https://clinicaltrials.gov/ct2/show/NCT00640315 (accessed 13 July 2015). ">NCT00640315</a>), systemic sclerosis (<a href="./references#CD011205-bbs2-0054" title="Bayer . Efficacy and safety of riociguat in patients with systemic sclerosis. https://clinicaltrials.gov/ct2/show/NCT02283762 (accessed 13 July 2015). ">NCT02283762</a>), idiopathic interstitial pneumonia (<a href="./references#CD011205-bbs2-0053" title="Bayer . Efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) (13605RISE‐IIP). https://clinicaltrials.gov/ct2/show/NCT02138825 (accessed 13 July 2015). ">NCT02138825</a>) and cystic fibrosis. In addition, despite thus far disappointing results in the use of riociguat in hearts with preserved systolic function, there are plans for a further parallel randomised controlled phase II trial (SOCRATES) investigating the use for associated PH (<a href="./references#CD011205-bbs2-0055" title="PieskeB , ButlerJ , FilippatosG , LamC , MaggioniAP , PonikowskiP , et al. Rationale and design of the SOluble guanylate cyclase stimulatoR in heArT failurE studies (SOCRATES). European Journal of Heart Failure2014;16(9):1026‐38. ">Pieske 2014</a>) as well as similar trials for verciguat. Results from well‐designed RCTs in these areas are strongly needed. There is also a call for studies providing greater detail on effects in children, and the effect of sGC stimulators relative to alternative treatment options in both PAH (e.g. parallel trials vs. PDE5is) and CTEPH (e.g. parallel trials vs. balloon angioplasty). </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011205-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study Selection Flow diagram." data-id="CD011205-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study Selection Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011205-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011205-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011205-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ricociguat versus placebo, Outcome 1 Change in Exercise Capacity (6MWD)." data-id="CD011205-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ricociguat versus placebo, Outcome 1 Change in Exercise Capacity (6MWD).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#CD011205-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011205-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ricociguat versus placebo, Outcome 2 Mortality." data-id="CD011205-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ricociguat versus placebo, Outcome 2 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#CD011205-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011205-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ricociguat versus placebo, Outcome 3 Improvement in WHO Functional Class." data-id="CD011205-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ricociguat versus placebo, Outcome 3 Improvement in WHO Functional Class.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#CD011205-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011205-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ricociguat versus placebo, Outcome 4 Clinical worsening." data-id="CD011205-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Ricociguat versus placebo, Outcome 4 Clinical worsening.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#CD011205-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011205-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ricociguat versus placebo, Outcome 5 Serious Adverse Events (Participants with one or more events)." data-id="CD011205-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Ricociguat versus placebo, Outcome 5 Serious Adverse Events (Participants with one or more events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#CD011205-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011205-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/urn:x-wiley:14651858:media:CD011205:CD011205-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_t/tCD011205-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ricociguat versus placebo, Outcome 6 Change in Mean Pulmonary Artery Pressure." data-id="CD011205-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Ricociguat versus placebo, Outcome 6 Change in Mean Pulmonary Artery Pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#CD011205-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/media/CDSR/CD011205/image_n/nCD011205-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011205-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings table</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Riociguat compared to placebo for pulmonary hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> Adults (&gt;18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)<br/> <b>Setting:</b> Randomised controlled trials of 16 weeks duration or less<br/> <b>Intervention:</b> Ricociguat<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Aetiology</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Ricociguat</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Change in Exercise Capacity (6MWD)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in Exercise Capacity (6MWD) ‐ Group 1: PAH in the intervention group was <b>12 m higher</b> (45 fewer to 69 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in Exercise Capacity (6MWD) ‐ Group 4: CTEPH in the intervention group was <b>45 m higher</b> (24 m more to 66 m more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Note small effect size</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.29</b> <br/> (0.05 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.57</b> <br/> (0.42 to 50.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (2 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.30</b> <br/> (0.05 to 1.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Improvement in WHO Functional Class</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235 per 1000<br/> (128 to 315) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.53</b> <br/> (0.87 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>217 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (102 to 325) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.84</b> <br/> (0.41 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>149 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 per 1000<br/> (201 to 490) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.80</b> <br/> (1.43 to 5.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Serious Adverse Events (Participants with one or more event)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<br/> (49 to 472) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.93</b> <br/> (0.22 to 3.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 2: Left heart disease</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335 per 1000<br/> (201 to 502) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.56</b> <br/> (0.78 to 3.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196 per 1000<br/> (110 to 326) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.29</b> <br/> (0.65 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CTEPH:</b> Chronic Thromboembolic Pulmonary Hypertension <b>CI:</b> Confidence interval; <b>PAH:</b> Pulmonary arterial hypertension; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>WHO:</b> World Health Organization; <b>6MWD:</b> 6‐minute walk distance </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Downgraded due to indirectness (variable treatment regimens in included studies) </p> <p><sup>2</sup> Downgraded due to imprecision in outcome </p> <p><sup>3</sup> Downgraded due to heterogeneity (I² &gt; 50%) </p> <p><sup>4</sup> Note that the pooled outcome includes data from trials with contra‐indicated drugs (PDE5is) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011205-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of Terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cyanosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A blue discolouration of the skin secondary to poor circulation or blood oxygenation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty in breathing</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient loss of consciousness and posture due to inadequate perfusion of the brain</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of Terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011205-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies summary</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PH Type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of Countries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number Completed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention Group PH Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control Group PH Treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial Phase</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 2: left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2 mg three times daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IIb</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 2: left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat 0.5 mg, 1 mg, or 2 mg.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IIa</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2 mg three times daily. People on stable sildenafil therapy at point of selection. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo with sham titrations. People on stable sildenafil therapy at point of selection.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2.5 mg three times daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo with sham titrations.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Riociguat, dose titrated up to 2.5 mg three times daily.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo with sham titrations.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>CTEPH:</b> Chronic Thromboembolic Pulmonary Hypertension; <b>PAH:</b> Pulmonary arterial hypertension </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies summary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011205-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Parameters relevant to protocol studied</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in 6MWD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical Worsening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious Adverse Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in mean PA pressure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0001" title="BondermanD , GhioS , FelixSB , GhofraniH‐A , MichelakisE , MitrovicV , et al. Riociguat for HF with pulmonary hypertension (PH): Post‐hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG). Journal of Cardiac Failure2014;20(8):S9. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisE , MitrovicV , et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic study. Circulation2013;128(5):502‐11. BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post‐hoc analysis of the phase IIB double‐blind, randomized, placebo‐controlled, dose‐ranging hemodynamic LEPHT study. American Heart Association Scientific Sessions; 2013 Nov 16‐20; Dallas. 2013; Vol. 128:A17234. GhioS , BondermanD , FelixSB , GhofraniHA , MichelakisED , MitrovicV , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure2012;14(8):946‐53. SemigranM , BondermanD , GhioS , FelixSB , GhofraniHA , MichelakisED , et al. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT). Circulation2012;126(23):2789‐90. ">Bonderman 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0002" title="BondermanD , PretschI , Steringer‐MascherbauerR , JansaP , RosenkranzS , TufaroC , et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension. Chest2014;146(5):1274‐85. BondermannD , PretschI , Steringer‐MascherbauerR , RosenkranzS , TufaroC , FreyR , et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE‐1): A randomized, double‐blind, placebo‐controlled, single‐dose study. European Heart Journal2013;34(suppl 1):620 [P3321]. ">Bonderman 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0003" title="GalileN , MullerK , ScaliseAV , GrunigE . PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH. European Respiratory Journal2015;45(5):1314‐22. GalièN , NeuserD , MullerK , ScaliseA‐V , GrünigE . A placebo‐controlled, double‐blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). American Journal of Respiratory and Critical Care Medicine2013;187:A3530. HumbertMJC , GalieN , GhofraniHA , JansaP , KeoghAM , LanglebenD , et al. Efficacy of riociguat in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of Respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3534. ">Galiè 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0004" title="GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , KeoghAM , et al. Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:346s [1784]. GhofraniH , GalieN , GrimmingerF , HumbertM , KeoghA , LanglebenD , et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study (PATENT‐1) [Abstract]. Chest2012;142(4):1027A. GhofraniHA , GalieN , GrimmingerF , GrunigE , HumbertM , JingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2013;369(4):330‐40. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StahlerG , BehrJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long‐term safety, tolerability, and efficacy [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A2370. GrunigE , GaileN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study. European Respiratory Society Annual congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GrünigE , GalièN , HumbertM , KeoghAM , LanglebenD , RubinLJ , et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona2013;42(Suppl 57):346s [1783]. GrünigE , SikiricaM , CurramJ , DavieN , GohfraniHA . Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent‐1 study. Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106. November 2013. JingJC , GaileN , GhofraniHA , HumbertM , LanglebenD , RubinLJ , et al. Comparison of hemodynamic parameters in treatment‐naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT‐1 study. European Heart Journal.2013;34(1):44‐6. LanglebenD , GalieN , HeJ , HuangY , HumbertM , KeoghAM , et al. Baseline characteristics and response to treatment in pretreated versus treatment‐naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT‐1 study. American Journal of respiratory and Critical Care Medicine2013;187(Meeting Abstracts):A3532. LanglebenD , GalièN , HeJ , HuangY , HumbertM Keogh A , et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT‐1 study. Journal of Heart and Lung Transplantation2015;34(3):338‐47. MeyerG , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Long‐term riociguat treatment in PAH patients in WHOfunctional Class (FC) I/II Versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2open‐label extension. Chest2013;145((3 Suppl)):513A. MeyerG , GalièN , GrimmingerF , GrünigE , HumbertM , JingZ‐C , et al. Long‐term riociguat treatment in PAH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 12‐week phase III PATENT‐1 study and PATENT‐2 open‐label extension [Abstract]. American College of Chest Physicians World Congress; 2014 Oct 25‐30; Austin. 2014; Vol. 145:513A. RubinL , GaileN , GrimmingerF , GrunigE , HumbertM , JingZ‐C . Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1‐Year results from the PATENT‐2 long‐term extension study. Chest2013;144(4):1024A. RubinLJ , GalièN , GrimmingerF , GrunigE , HumbertM , ZingZC , et al. Riociguat for the treatment of pulmonary arterial hypertension: a long‐term extension study (PATENT‐2). European Respiratory Society2015;45(5):1303‐13. RubinRJ , GaileN , GrimmingerF , GrunigE , HumbertMJ , JingZ‐C , et al. Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long‐term extension study (patent‐2). American Thoracic Society International Conference, May 17‐22, 2013, Philadelphia, Pennsylvania, USA. 2013. ">Ghofrani 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011205-bbs2-0005" title="D'ArminiAM , GhofraniH‐A , KimNH , MayerE , SimonneauG , WilkinsMR , et al. Riociguat for the treatment of inoperable CTEPH or persistent/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST‐1 study [Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42:543s [P2598]. D'ArminiAM , GhofraniHA , KimNH , MayerE , MorsoliniM , Pulido‐ZamudioT . Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST‐1 study. Journal of Heart and Lung Transplantation2015;34(3):348‐55. GhofraniH , GrimmingerF , HoeperM , KimN , MayerE , NeuserD , et al. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double‐blind, placebo‐controlled study (CHEST‐1) [Abstract]. Chest2012;142(4):1023A. GhofraniH‐A , GrimmingerF , HoeperMM , KimNH , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract]. European Respiratory Society 23rd Annual Congress; 2013 Sep 7‐11; Barcelona. 2013; Vol. 42, issue Suppl 57:701s [P3418]. GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , KimNH , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. GhofraniHA , GrimmingerF , HoeperM , KimN , MayerE , SimonneauG , et al. Impact of riociguat on health‐related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). European Respiratory Society Annual Congress, 2013 Sept 7‐11, Barcelona, Spain. 2013. GhofraniHA , HoeperMM , HalankM , MeyerFJ , StaehlerG , BehrfJ , et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal2010;36(4):792‐9. JansaP , GhofraniH‐A , HoeperMM , KimNH , MayerE , NeurohrC , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal2013;34(suppl 1):187. JansaP , GhofraniHA , KimNH , MayerE , NeurohrC , SimonneauG , et al. Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST‐1 study. European Heart Journal.2013;34(1):187. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4_MeetingAbstracts)):1023A. SimonneauG , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperMM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long‐term extension study (CHEST‐2). European Respiratory Journal2015;45(5):1293‐302. SimonneauG , D’ArminiA , GhofraniH , GrimmingerF , HoeperM , JansaP , et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1‐year results from the CHEST‐2 long‐term extension study [Abstract]. Chest2013;144(4 Meeting Abstracts):1023A. WangC , D'ArminiAM , GhofraniHA , GrimmingerF , HoeperM , JansaP . Long‐term riociguat treatment in inoperable and persistent/recurrent CTEPH patients in WHO functional class (FC) I/II versus FC III/IV at baseline: results from the 16‐week phase III CHEST‐1 study and CHEST‐2 open‐label extension [Abstract]. Chest2014;145(3 Suppl):535B. ">Ghofrani 2013b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>"1" = Primary outcome measure of study. "2" = Secondary outcome measure of study. "3" = Parameter measured but not explicitly as a primary or secondary outcome. "‐" = measure not included in study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Parameters relevant to protocol studied</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/full#CD011205-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011205-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ricociguat versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in Exercise Capacity (6MWD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.13 [5.29, 54.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.91 [‐44.92, 68.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Group 2: Left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>45.0 [23.87, 66.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.18, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.05, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Group 2: Left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.57 [0.42, 50.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.05, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement in WHO Functional Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.87, 2.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.87, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Group 2: Left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.41, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.80 [1.43, 5.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical worsening <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Group 2: Left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.41, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.10, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious Adverse Events (Participants with one or more events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.66, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.22, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Group 2: Left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.78, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.65, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in Mean Pulmonary Artery Pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.77 [‐4.96, ‐0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Group 1: PAH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.5 [‐5.54, ‐1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Group 2: Left heart disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐3.29, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Group 4: CTEPH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.8 [‐6.71, ‐2.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ricociguat versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011205.pub2/references#CD011205-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011205.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011205-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011205-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011205-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD011205-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011205\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011205\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011205\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011205\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011205\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011205.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011205.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011205.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011205.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011205.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727712632"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011205.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727712636"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011205.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb2c169ae936d',t:'MTc0MDcyNzcxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 